Résultats de la recherche

search
Logo 1200x628.jpg
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
26 févr. 2025 07h00 HE | CytoSorbents
CytoSorbents Announces Fourth Quarter and Full Year 2024 Earnings Release Date for March 6, 2025
Logo 1200x628.jpg
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
25 févr. 2025 07h00 HE | CytoSorbents
CytoSorbents Strengthens Balance Sheet with Additional $1.6M in Aggregate Gross Proceeds from Shareholder Exercise of Series A Right Warrant
Logo 1200x628.jpg
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
12 déc. 2024 07h00 HE | CytoSorbents
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.
Logo 1200x628.jpg
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07 nov. 2024 16h05 HE | CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Logo 1200x628.jpg
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
01 août 2024 07h00 HE | CytoSorbents
CytoSorbents regains compliance with Nasdaq minimum bid price requirement
Logo 1200x628.jpg
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
30 juil. 2024 02h00 HE | CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Logo 1200x628.jpg
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
29 juil. 2024 08h00 HE | CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Logo 1200x628.jpg
CytoSorbents Secures $20 Million Credit Facility
02 juil. 2024 07h00 HE | CytoSorbents
$20 million credit facility provides CytoSorbents with important non-dilutive capital to support its regulatory and commercialization objectives
Logo 400x400.jpg
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 déc. 2023 07h00 HE | CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
Logo 400x400.jpg
CytoSorbents to Present at the 8th Annual Dawson James Conference
05 oct. 2023 07h00 HE | CytoSorbents
CytoSorbents to Highlight Company Progress at Dawson James Small Cap Investor Growth Conference